Randomized study of Lacticaseibacillus fermented milk in Indonesian elderly houses: Impact on gut microbiota and gut environment

Table 6 Number and percentage of participants with adverse events, n (%)

	Placebo	Probiotic	Odds ratio	P value
Any adverse event	22 (40.7)	21 (38.9)	0.87	0.845
Gastrointestinal disorders	8 (14.8)	6 (11.1)	0.69	0.577
Diarrhea	2 (3.7)	2 (3.7)	0.96	1.000
Stomatitis	1 (1.9)	0 (0)	0.32	0.491
Stomachache	2 (3.7)	1 (1.9)	0.47	0.615
Toothache	1 (1.9)	1 (1.9)	0.96	1.000
Pain of epigastrium	1 (1.9)	2 (3.7)	1.96	0.514
Bloated	0 (0)	2 (3.7)	5.00	0.496
Gastric pain	0 (0)	1 (1.9)	2.95	1.000
Dyspepsia syndrome	1 (1.9)	0 (0)	0.32	0.491
Lower abdominal pain	1 (1.9)	0 (0)	0.32	0.491
Nausea	0 (0)	1 (1.9)	2.95	1.000
Nervous system disorders	5 (9.3)	8 (14.8)	1.63	0.557
Musculoskeletal and connective tissue disorders	5 (9.3)	6 (11.1)	1.18	1.000
General disorders and administration site conditions	4 (7.4)	5 (9.3)	1.23	0.523
Respiratory, thoracic, and mediastinal disorders	4 (7.4)	1 (1.9)	0.23	0.202
Infections and infestations	2 (3.7)	2 (3.7)	0.96	1.000
Skin and subcutaneous tissue disorders	2 (3.7)	1 (1.9)	0.47	0.615
Eye disorders	1 (1.9)	1 (1.9)	0.96	1.000
Metabolism and nutrition disorders	0 (0)	1 (1.9)	2.95	1.000
Vascular disorders	0 (0)	1 (1.9)	2.95	1.000
Psychiatric disorders	1 (1.9)	0 (0)	0.32	0.491